The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
Annovis Bio (NYSE: ANVS), a late-stage drug developer, has announced new data from its Phase III study of Parkinson’s candidate buntanetap. 3 July 2024
Cambridge, UK-based Mission Therapeutics, a clinical-stage biotech, has received $5.2 million in funding from The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK. 2 July 2024
China’s Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved Japanese pharma major Astellas’ Xtandi (enzalutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). 2 July 2024
Amylyx Pharmaceuticals (Nasdaq: AMLX) has acquired the rights to Eiger Biopharmaceuticals’ (Nasdaq: EIGR) experimental drug avexitide for $35.1 million. 2 July 2024
US pharma major Eli Lilly has followed up last year’s $1.4 billion acquisition of radiopharmaceuticals firm POINT Biopharma Global with another deal in the field. 2 July 2024
In the USA, two New Drug Applications (NDA) for crinecerfont have been accepted by the US regulator, and will be considered under the Priority Review scheme. 1 July 2024
NeuroSense Therapeutics (Nasdaq: NRSN), a late-clinical stage biotech firm, has announced significant findings from its 12-month Phase IIb PARADIGM study. 1 July 2024
A co-development deal between Finland’s Orion Corporation (HEL: ORNAV) and Merck & Co (NYSE: MRK) has been upgraded to an exclusive global licensing agreement. 1 July 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024